Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.59 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.56 |
| ▸ | WNT3A | P56704 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629579 | 0.91 | CTNNB1 (0.68) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL11022828 | 0.88 | HPGD (0.70) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL10781619 | 0.87 | ATM (0.69) | ATMTAS1R3TAS1R1CTNNB1WNT3A | |
| SCHEMBL14044259 | 0.85 | PRKCI (0.58) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL6181845 | 0.84 | PRKCI (0.57) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL1182701 | 0.84 | PRKCI (0.57) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL13516241 | 0.82 | MEN1 (0.63) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL852863 | 0.82 | ALDH1A1 (0.56) | ATMTAS1R3TAS1R1PRKCICTNNB1 | |
| SCHEMBL102518 | 0.81 | PRKCI (0.62) | TAS1R3TAS1R1PRKCICTNNB1WNT3A | |
| SCHEMBL29793780 | 0.81 | PRKCI (0.62) | TAS1R3TAS1R1PRKCICTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61148172-A | — | — | None | — | — | JP | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-115710179-A | Method for synthesizing alpha-acyloxy ketone by photocatalysis | 浙江工业大学台州研究院 | 2023-02-24 | — | — | CN | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| CN-100400041-C | Diaminothiazoles useful as selective inhibitors of CDK4 | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| US-20070010568-A1 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORY LIMITED (IN) | 2007-01-11 | — | — | US | disclosed |
| US-20070010568-A1 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORY LIMITED (IN) | 2007-01-11 | — | — | US | disclosed |
| CN-1652780-A | Diaminothiazoles used as CDK4 inhibitors | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
| JP-S61148172-A | 1-(2,3-DIHYDRO-5-BENZOFURANYL)-1-PROPANONE DERIVATIVE, AND CENTRAL MUSCLE RELAXANT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT | TOKYO TANABE CO LTD | 1986-07-05 | — | — | JP | disclosed |
| EP-0163537-A1 | 1-Propanone derivatives and pharmaceutical compositions containing same | TOKYO TANABE COMPANY LIMITED (JP) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010568-A1 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ATM 3986/4885TAS1R3 2273/4885TAS1R1 2080/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | ATM 318/4885TAS1R3 4882/4885TAS1R1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.